TP53 co-mutations in advanced lung adenocarcinoma: comparative bioinformatic analyses suggest ambivalent character on overall survival alongside KRAS, STK11 and KEAP1 mutations

Abstract excerpt

Background Recently, we could show that the co-mutations of KRAS + KEAP1 , STK11 + KEAP1 and KRAS + STK11 + KEAP1 lead to a significantly shorter median overall survival (mOS) in patients with lung cancer across treatments by analyzing multiple dataset. TP53 , a tumor suppressor gene, plays a crucial role in regulating cell cycle progression. Its mutations occur in approximately 40-50% of non-small lung cancer...

Topics

Join the communities discussing this publication.

• Cancer Genomics and Diagnostics
• Lung Cancer Treatments and Mutations
• Melanoma and MAPK Pathways